T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Weight loss drugs catapulted many into a new wellness era ... of new drugs looking to enter the market. Between August 2021 and August 2023, the prevalence of obesity among adults was 40.3 ...
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...
Nearly half of US adults admit they’d take one of the newer, injectable weight loss ... 2021 to December 2023, of which 58.9% were female. The overall prevalence of discontinuation of GLP-1 ...
Industry lobbyists maintain that this will reduce investment in new pill medications even if they may be the most effective and affordable option for patients. In addition to the weight-loss ...
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback